The pandemic (H1N1) 2009 influenza virus is resistant to mannose-binding lectin by Tokunaga, Hirotoshi et al.
RESEARCH Open Access
The pandemic (H1N1) 2009 influenza virus is
resistant to mannose-binding lectin
Hirotoshi Tokunaga
1,2, Hiroshi Ushirogawa
1, Masanobu Ohuchi
1*
Abstract
Background: Mannose-binding lectin (MBL) is an important component of innate immunity because it promotes
bacterial clearance and neutralization of human influenza A viruses. Since a majority of humans have no
neutralizing antibody against the pandemic (H1N1) 2009 influenza (pandemic 2009) virus, innate immunity may be
crucial and MBL susceptibility may therefore influence viral pathogenesis.
Results: We examined MBL susceptibility of influenza A viruses and observed that the pandemic 2009 virus was
resistant to MBL, whereas all seasonal influenza A viruses tested were susceptible. The mortality of mice infected
with a seasonal H1N1 influenza virus was evidently enhanced on transient blockage of MBL activity by
simultaneous inoculation of mannan, whereas mannan inoculation had no effect on mice infected with a
pandemic 2009 virus. This indicates that MBL protects mice against infection with the seasonal virus but not
against that with the pandemic 2009 virus.
Conclusions: These results indicate that the pandemic 2009 virus is not susceptible to MBL, an important
component of innate immunity.
Background
A novel influenza virus of swine origin, which emerged
in North America in 2009, rapidly spread worldwide
and caused the influenza pandemic 2009. This virus was
classified as type A and subtype H1N1 according to the
antigenicity of hemagglutinin (HA) and neuraminidase
proteins [1]. Currently, the pandemic 2009 caused due
to influenza H1N1 virus has ceased. However, in case of
the 1918 Spanish flu pandemic, low mortality was
observed at the first wave, followed by a second wave
that caused a severe pandemic with high mortality [2,3].
Whether a second wave of the pandemic (H1N1) 2009
will emerge is difficult to predict. Pathogenesis of the
pandemic (H1N1) 2009 influenza (pandemic 2009) virus
has not yet been completely elucidated. Pathogenesis of
a virus is not only determined by its ability to infect and
grow in its host but also by its interaction with host
defense mechanisms. Prior to an acquired immune
response, especially in case of primary infection with a
foreign pathogen, innate immunity is crucial for host
defense. Consequently, the susceptibility of a pathogen
to an innate immune response inevitably determines its
pathogenesis. Human seasonal influenza A viruses are
susceptible to mannan-binding protein, also known as
mannose-binding lectin (MBL) [4-9], which is an acute
protein produced by the liver [10,11]. Usually, the blood
MBL level may not be sufficiently high to directly inhibit
initial infection with the influenza virus. However, when
MBL production is upregulated in response to inflam-
mation, MBL may restrict the development of viral
infection in the host. Thus, it is expected to function as
a “brake” towards inhibiting the viral propagation.
Therefore, MBL susceptibility of the pandemic 2009
virus must be determined in order to discuss the patho-
genesis of this virus and the potential toward causing a
severe second wave of pandemic.
Results
MBL susceptibility of the pandemic 2009 virus
We compared MBL susceptibility of the seasonal and
pandemic viruses using normal mouse sera, because of
the following reasons. First, human-derived products
such as human MBL are not commercially available.
Second, most human serum contains a high titer of
* Correspondence: mohuchi@med.kawasaki-m.ac.jp
1Department of Microbiology, Kawasaki Medical School, 577 Matsushima,
Kurashiki, Okayama 701-0192, Japan
Full list of author information is available at the end of the article
Tokunaga et al. Virology Journal 2011, 8:50
http://www.virologyj.com/content/8/1/50
© 2011 Tokunaga et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.neutralizing antibodies against the seasonal influenza
viruses, whereas the MBL content is usually low. Third,
mouse serum contains a high titer of MBL and the
sugar recognition specificity of murine MBL closely
resembles that of human MBL [5,7,12,13], and the mini-
mum concentration of murine MBL required to gener-
ate anti-influenza neutralizing activity almost closely
resembles that of human MBL [4,6,8,9]. Sera from naive
C57BL/10 mice were serially diluted 10-fold with Dul-
becco’s modified Eagle’s medium (DMEM), and this
mixture was then mixed with a virus suspension con-
taining approximately 1 × 10
2 plaque-forming units
(PFU) of the seasonal or the pandemic 2009 viruses, and
then incubated for 30 min at room temperature. The
mixtures were then inoculated into Madin-Darby canine
kidney (MDCK) cell cultures and assayed for viral infec-
tivity. Representative pictures of the plaque assay are
shown in Figure 1A. Plaques (represent infectivity) of
the seasonal A/Okayama/5/2000 (H1N1) virus were evi-
dently reduced when the virus suspension was pre-
treated with 1:100 diluted mice sera, whereas plaques of
the pandemic 2009 A/Chiba/1001/2009 virus were not
affected by the same pretreatment. The inhibitory effect
of the mice sera on the seasonal Okayama virus was
completely eliminated by the addition of mannose to
the pretreatment mixture, which clearly demonstrates
that the effect was mediated by MBL. The inhibitory
effects of the mice sera on the seasonal and pandemic
2009 viruses are shown in Figure 1B and Figure 1C,
respectively. All three seasonal influenza A viruses were
evidently neutralized with murine MBL, whereas the
pandemic 2009 viruses tested did not show any MBL
susceptibility. Similar results were obtained in experi-
ments with BALB/c mice sera and other seasonal and
pandemic 2009 strains (data not shown). These results
demonstrate that the pandemic 2009 virus lacks MBL
susceptibility.
Glycosylation site of the HA protein responsible for MBL
susceptibility
The HA protein of the human influenza H3N2 virus dis-
plays a mannose-rich glycan at the N-glycosylation site of
amino acid 165 (asparagine) [14]. MBL binds to this gly-
can and because of its proximity to the receptor-binding
site; MBL inhibits viral access to the receptors [4,7]. This
glycosylation motif is highly conserved in all human
H3N2 viruses. In order to determine the presence of
such a motif in the HA protein of the seasonal and pan-
demic H1N1 viruses tested in this study, we directly
sequenced HA genes of the seasonal Okayama/5/2000 as
well as pandemic Chiba/1001/2009, and Kurashiki/3/
2009 viruses. As shown in Fi g u r e2 A ,t h es e a s o n a l
Okayama virus has a glycosylation motif at amino acid
163 (H3 alignment numbering), whereas the pandemic
Chiba/1001 and Kurashiki/3 viruses have no glycosyla-
tion motif in this region. The same pattern has been
observed in almost all other seasonal and pandemic
H1N1 viruses [15]. This amino acid 163 site of the H1
HA protein has shown to be glycosylated [16]. The
deduced location of the glycan is shown in Figure 2B.
The infectivity of seasonal influenza A viruses can be
neutralized by the binding of MBL to the glycan in this
region.
Contribution of MBL to host defense in mice infected
with seasonal or pandemic 2009 viruses
We confirmed the MBL susceptibility of seasonal and
pandemic viruses in a mouse infection model. Although,
the MBL level in mouse serum is always high [4], intra-
nasal inoculation of mannan in the mouse respiratory
tract transiently blocks the MBL activity [8]. The block-
ing of MBL activity considerably affects the progress of
viral infection in cases wheret h ev i r u si ss u s c e p t i b l et o
MBL. If the virus is resistant to MBL, the progress of
infection is not affected by mannan inoculation. Mice
were intranasally inoculated with 20 μl of virus suspen-
sion with or without 1% mannan. After infection, the
body weight of the mice was monitored daily until day
28. Histopathological examination of the lungs of the
infected mice with weight loss revealed pneumonia with
cellular infiltration (Figure 3). Mortality of the infected
mice is shown in Figure 4A. Mortality in mice infected
with the seasonal Okayama/5/2000(H1N1) virus evi-
dently increased on simultaneous inoculation of 1%
mannan, whereas such an effect was not observed in
those infected with the pandemic 2009 Chiba virus. The
severity of infection in each mice were scored according
to the maximum loss of body weight (%) [no loss was
scored as 0 (no symptom); ≤10% was scored as 1 (mild);
>10% to ≤20% was scored as 2 (moderate); >20% was
scored as 3 (severe); and death was scored as 4 (fatal)].
As shown in Figure 4B, when MBL activity was transi-
ently blocked by simultaneous inoculation of mannan,
the symptoms became more severe in the mice infected
with the seasonal virus (p <0 . 0 0 1 ,W e l c h ’s two-tailed t-
test), whereas no change was observed in those infected
with the pandemic 2009 virus. These findings confirm
that MBL actually contributes to host defense in mice
infected with MBL susceptible viruses, and that the pan-
demic 2009 virus is resistant to MBL.
Discussion
Human influenza A viruses excluding mouse-adapted
viruses have a glycosylation site at amino acid 165 of the
HA protein [14]. Glycan at amino acid 165 of the H3 HA
protein is rich in mannose, and is thus responsible for
MBL susceptibility of human H3N2 influenza viruses
[4,7]. The 1918 Spanish flu virus has no glycosylation site
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Page 2 of 8Figure 1 MBL Susceptibility of seasonal and pandemic 2009 viruses.( A )P l a q u e sw e r ev i s u a l i z e db yi m m u n o s t a i n i n g .T oe l i m i n a t et h e
effects of MBL, the mouse serum was diluted with DMEM containing 0.1 M mannose. (B and C) Inhibitory effect of mouse serum on seasonal
and pandemic 2009 influenza viruses. The infectivity of each specimen was expressed as a percentage of the plaque number of the control
(without mouse serum). Each value is the mean derived from two independent experiments.
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therefore, it might be resistant to MBL. Through reverse
genetics, Kobasa et al. substituted the HA protein of a
human-origin influenza virus with that of the Spanish flu
virus and found that the resulting virus caused severe
pneumonia with extensive cellular infiltration in mice
[18]. They proposed that the high pathogenicity of this
virus was due to an abnormality in the innate immune
response of the mice. Accordingly, we suggest that MBL,
which is an important component of innate immunity,
might fail to neutralize this virus in the mouse lung.
This raises the question as to why the pandemic 2009
virus is not as virulent in humans as the Spanish flu
virus. In our experiments with human-origin cell cul-
tures (unpublished data), the growth rate of the pan-
demic 2009 virus was distinctly lower than that of
seasonal H3N2 and H1N1 viruses, suggesting that the
pandemic virus may not yet have adapted sufficiently to
the human cells. Thus, the pandemic 2009 virus can
potentially cause a severe second wave of pandemic,
once it acquires such a high growth rate in humans.
Although the advantage of the presence of a mannose-
rich glycan at the tip of the HA protein of the virus
remains unclear, it may attenuate viral pathogenesis,
facilitating patient mobility and thereby contributing to
wide dissemination of the virus, even after a large popu-
lation of humans has obtained immunity against it. By
1933, a descendant of the Spanish flu virus obtained a
glycosylation site at amino acid 165 of the HA protein
to which a mannose-rich glycan could attach [15]. Since
no virus was isolated from humans before 1933, the
exact year of this development remains unknown.
In the database of influenza viruses, four pandemic
2009 isolates with the glycosylation motif at amino acid
165 in the HA protein have been reported [19], which
were first isolated in Novouralsk, Russia (November
2009) and later in Orenburg, Russia (March 2010). Both
of these regions are located in Central Asia, and the
nucleotide sequence homology of HA is >99.6% among
the isolates [20], suggesting that they belong to the
same lineage. This lineage may be either extinct or pre-
sent in an extremely lower number of human popula-
tions. Such MBL susceptible viruses may have no
competitive advantage in the present situation, wherein
a majority of people have no immunity against the virus.
The contribution of MBL to host defense in influenza
infection has not yet been completely elucidated.
Regarding the innate host defense mechanism in
respiratory organ, surfactant protein D (SP-D) and A
(SP-A) should be considered as the most potent factors
in the defense mechanism [21-23]. Since SP-D is known
to show sugar specificity similar to MBL [21], it would
be interesting to examine the susceptibility of the pan-
demic 2009 virus to SP-D and also to SP-A. These fac-
tors will now be of utmost importance towards
advancing our understanding of influenza pathogenesis.
Figure 2 Glycosylation motif around amino acid 165 of the HA protein of seasonal H1N1 and pandemic 2009 viruses. (A) Amino acid
sequence. Okayama/5/2000, seasonal virus; Chiba/1001/2009 and Kurashiki/3/2009, pandemic 2009 viruses. ● indicates the same amino acid as
that in Okayama/5/2000. Red letters indicate N-glycosylation motif. (B) The deduced location of the glycosylation site in the 3D model of the HA
protein [14].
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urgently required in this area of research.
Conclusions
The pandemic 2009 influenza virus is not susceptible to
MBL, and therefore, the MBL resistance property of this
virus may be one of its potential pathogenic factors.
Methods
Viruses and cells
Pandemic influenza A/Chiba/1001 and 1007/2009 (H1N1)
v i r u s e sw e r ep r o v i d e db yD r .O g a w aTf r o mt h eC h i b a
Prefectural Institute of Public Health. The A/Kurashiki/3/
2009 (H1N1) virus was isolated in our laboratory. For sea-
sonal influenza viruses, we used A/USSR/90/1977 (H1N1)
(provided by Dr. Nobusawa R from the Nagoya City Uni-
versity), A/Okayama/5/2000 (H1N1), and A/Okayama/6/
2001 (H3N2) (both isolated in our laboratory). Each virus
s t o c kw a sp u r i f i e dt w i c eb ylimiting dilutions through
MDCK cells grown in a 12-well plate and then propagated
once in MDCK cells in a bottle. The passage number of
Chiba, Kurashiki, and Okayama strains used in the present
study was between 5 and 7. The USSR/77 virus was propa-
gated once in an embryonated chicken egg.
MDCK cells were grown in Eagle’s minimum essential
medium supplemented with 10% fetal calf serum (FCS).
For viral infection, MDCK cells were washed twice with
FCS-free medium and then supplemented with fresh
DMEM. All viral experiments were performed in a level
2 biosafety laboratory.
Assay of viral infectivity
MDCK cells propagated in a 12-well culture plate were
inoculated with virus suspensions and incubated for 1 h
at 37°C, and then the culture medium was replaced
with DMEM containing 0.6% agarose and 1 μg/ml
Figure 3 Histopathological observation of the lungs of virus-inoculated mice. On day 8 after infection, the lungs were removed from the
mice under anesthesia and subjected to histopathological examination. Lung section of the mouse co-inoculated with mannan is also shown.
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Figure 4 Effect of mannan inoculation on influenza virus infection in mice. (A) Mortality of mice infected with seasonal or pandemic 2009
viruses. Each mouse was intranasally inoculated with 20 μl of virus suspension (containing 0% or 1% mannan) under anesthesia. (B) The severity
of infection in each mouse was scored according to the maximum loss of body weight (% of weight on day 0 after infection), and mice with
the same score were summed together.
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Page 6 of 8acetylated trypsin (Sigma, USA). In agarose-containing
medium, trypsin-activated progeny viruses infected only
neighboring cells and thus formed a plaque. Accord-
ingly, one PFU was considered to correspond to one
infectious virus. Two days after virus inoculation, the
plaques were stained with anti-influenza A virus guinea
pig antiserum (prepared in our laboratory), and peroxi-
dase-conjugated goat anti-guinea pig IgG (Jackson
Immuno Research, USA).
Neutralization of viral infectivity with murine MBL
Sera were prepared from 3.5- to 7.5-week-old naive
C57BL/10slc or BALB/c mice (SLC Laboratory, Japan).
In order to measure the virus neutralizing activity,
serum was serially diluted 10-fold with DMEM, and
then mixed with the virus suspension. To block MBL
activity, the serum was diluted with DMEM containing
0.1 M mannose (Sigma, USA). After incubating the mix-
tures for 30 min at room temperature, they were inocu-
lated into MDCK cell cultures to determine the
remaining infectivity.
Sequence analysis of the region around amino acid 165
in the HA protein
Virus suspension (1.5 ml) was centrifuged at 10,000 × g
for 90 min at 4°C, and RNA was extracted from the pre-
cipitate using Isogen (Wako Chemicals, Japan). HA
cDNA was synthesized from RNA by RT-PCR using
specific primers. The PCR product was subjected to
agarose gel electrophoresis, and the specific band was
excised from the gel and purified using a QIAquick Gel
Extraction Kit (Qiagen, Germany). Sequencing was per-
formed using the same primers as those used in RT-
PCR. The primers used for the seasonal Okayama/5/
2000 strain were huH1-257 (forward, 5’-TAC TGA TTT
CCA AGG AGT C-3’) and huH1-885 (reverse, 5’-CTT
CGC ATC ACA TTT ATC CAT-3’), and those used for
the pandemic Chiba/1001/2009 and Kurashiki/3/2009
strains were swH-257 (forward, 5’-CAC TCT CCA CAG
CAA GCT C-3’) and swH-885 (reverse, 5’-AGT TGT
ATT GCA ATC GTG GAC-3’), respectively. The
nucleotide sequences were deposited in the DNA Data
Bank of Japan (accession number AB568299-301).
Experimental infection of mice with seasonal and
pandemic viruses
Female 3.5-week-old C57BL/10slc or BALB/c mice were
intranasally inoculated with a 20 μl suspension of the
seasonal Okayama/5/2000(H1N1) or pandemic 2009
Chiba/1001/09(H1N1) viruses under anesthesia with
sevoflurane. The body weight of each mouse was moni-
tored daily. For histopathological examination, lungs
were removed from several mice on day 8 after infec-
tion. At the end of the experiment, blood samples were
collected from the surviving mice under anesthesia and
the anti-influenza antibody titer in the serum was
assayed to confirm infection; this analysis was performed
even for asymptomatic mice.
To temporarily block MBL activity in mice, soluble
mannan (Sigma, USA) was added to the virus suspen-
sion at a final concentration of 1% (w/v). Severity scores
of the infected mice administrated with and without
mannan were statistically compared using Welch’st w o -
tailed t-test. This experiment was approved by the Ani-
mal Experiment Committee of Kawasaki Medical School
(Approval No. 09-066) and performed in a P2A level
laboratory.
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